Key result
Atorvastatin reversed angiotensin II-induced upregulation of miRNA-22 and suppressed cardiac hypertrophy markers in vitro and in vivo.
Why the study?
Does atorvastatin reduce cardiac hypertrophy by modulating miRNA-22 expression in preclinical models?
Does atorvastatin reduce cardiac hypertrophy by modulating miRNA-22 expression in preclinical models?
Atorvastatin attenuates cardiac hypertrophy in preclinical models by downregulating miRNA-22 and modulating PTEN activity, suggesting a novel microRNA-based mechanism for its antihypertrophic effects.
Answers are grounded in this paper and cite their sources.
Supports miRNA-22 modulation as antihypertrophic mechanism in models; leaves open human translation and clinical relevance.
BACKGROUND: Growing evidence shows that microRNAs (miRNAs) are involved in various cardiac processes including cardiac hypertrophy. However, the modulation of miRNA by pharmacological intervention in cardiomyocyte hypertrophy has not been disclosed yet. methods: We constructed neonatal rat cardiomyocyte hypertrophy induced by angiotensin II stimulation and subjected to cardiomyocyte immunochemistry, qRT-PCR and immunoblotting analysis. In addition, we constructed the mouse cardiac hypertrophy using angomir-22 stimulation and demonstrated the potential antihypertrophic mechnism of atorvastatin. RESULTS: The results showed that a collection of miRNAs were aberrantly expressed in hypertrophic cardiomyocytes induced by angiotensin II stimulation. In addition, overexpression of miR-22 was found in angiotensin II-induced hypertrophic cardiomyocytes, whereas administration of atorvastatin could reverse the upregulation of miRNA-22 nearly back to the control level. Furthermore, up-regulation of miRNA-22 in cardiomyocytes in vitro and in vivo could induce cardiac hypertrophy, which could suppress the protein level of phosphatase and tensin homolog deleted on chromosome ten (PTEN). Concomitantly, the production of ANP, BNP and β-MHC was enhanced and cardiomyocyte size was increased. However, atorvastatin could markedly knockdown miRNA-22 expression and reverse these changes in cardiomyocytes. These results suggest that the contribution of atrovastatin to cardiomyocyte hypertrophy may be involved in downregulation of miRNA-22 expression, which modulates the activity of PTEN in cardiomyocyte hypertrophy. conclusion: This study demonstrates for the first time the modulation of miRNA-22 can be achieved by pharmacological intervention. The data generated from this study provides a rationale for the development of miRNA-based strategies for antihypertrophic treatment.
No takes yet. Share an insight, caveat, or question.
Tu et al. (2013) studied Cardiac hypertrophy. Atorvastatin vs. Control was evaluated on miRNA-22 expression and cardiac hypertrophy. Atorvastatin reversed angiotensin II-induced upregulation of miRNA-22 and suppressed cardiac hypertrophy markers in vitro and in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: